Related Experiment Video

Updated: Jun 25, 2026

Assaying the Kinase Activity of LRRK2 in vitro
06:09

Assaying the Kinase Activity of LRRK2 in vitro

Published on: January 18, 2012

The therapeutic potential of LRRK2 and alpha-synuclein in Parkinson's disease

Saurabh Sen1, Andrew B West

  • 1Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, University of Alabama School of Medicine, Birmingham, Alabama 35294, USA.

Antioxidants & Redox Signaling
|March 11, 2009
PubMed

Insights

Parkinson's disease treatments do not halt progression. Identifying targets like alpha-synuclein and LRRK2 is crucial for developing therapies that protect and restore neurons, but their exact role in neurodegeneration needs further research.

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Pharmacology

Background:

  • Current Parkinson's disease treatments are palliative and do not alter disease progression.
  • The molecular mechanisms driving Parkinson's disease pathogenesis remain largely unknown.
  • Identifying specific molecular targets is essential for developing effective neuroprotective and neurorestorative therapies.

Purpose of the Study:

  • To highlight alpha-synuclein and LRRK2 as key protein candidates for Parkinson's disease research.
  • To underscore the need for understanding the link between these proteins' functions and neurodegeneration.
  • To emphasize the requirement for novel technologies to target these proteins for therapeutic intervention.

Main Methods:

  • Review of current literature on Parkinson's disease.
  • Analysis of the roles of alpha-synuclein and LRRK2 in disease pathogenesis.
  • Discussion of technological needs for therapeutic development.

Main Results:

  • Alpha-synuclein and LRRK2 are implicated as significant targets in Parkinson's disease.
  • Evidence supports their role in disease, but the precise connection to neurodegeneration is unclear.
  • The therapeutic potential of targeting these proteins is contingent on developing specific mitigation technologies.

Conclusions:

  • Alpha-synuclein and LRRK2 represent promising therapeutic targets for Parkinson's disease.
  • Further research is needed to clarify their pathogenic roles and develop targeted interventions.
  • Technological advancements are critical to fully realize the therapeutic value of targeting these proteins.

More Related Videos

Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation12:49

Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation

Published on: March 21, 2020

Rab10 Phosphorylation Detection by LRRK2 Activity Using SDS-PAGE with a Phosphate-binding Tag08:55

Rab10 Phosphorylation Detection by LRRK2 Activity Using SDS-PAGE with a Phosphate-binding Tag

Published on: December 14, 2017

Related Concept Videos

Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...